+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention



Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention



Experimental Neurology 208(1): 1-25



Most acute and chronic neurodegenerative conditions are accompanied by neuroinflammation; yet the exact nature of the inflammatory processes and whether they modify disease progression is not well understood. In this review, we discuss the key epidemiological, clinical, and experimental evidence implicating inflammatory processes in the progressive degeneration of the dopaminergic (DA) nigrostriatal pathway and their potential contribution to the pathophysiology of Parkinson's disease (PD). Given that interplay between genetics and environment are likely to contribute to risk for development of idiopathic PD, recent data showing interactions between products of genes linked to heritable PD that function to protect DA neurons against oxidative or proteolytic stress and inflammation pathways will be discussed. Cellular mechanisms activated or enhanced by inflammatory processes that may contribute to mitochondrial dysfunction, oxidative stress, or apoptosis of dopaminergic (DA) neurons will be reviewed, with special emphasis on tumor necrosis factor (TNF) and interleukin-1-beta (IL-1beta) signaling pathways. Epigenetic factors which have the potential to trigger neuroinflammation, including environmental exposures and age-associated chronic inflammatory conditions, will be discussed as possible 'second-hit' triggers that may affect disease onset or progression of idiopathic PD. If inflammatory processes have an active role in nigrostriatal pathway degeneration, then evidence should exist to indicate that such processes begin in the early stages of disease and that they contribute to neuronal dysfunction and/or hasten neurodegeneration of the nigrostriatal pathway. Therapeutically, if anti-inflammatory interventions can be shown to rescue nigral DA neurons from degeneration and lower PD risk, then timely use of anti-inflammatory therapies should be investigated further in well-designed clinical trials for their ability to prevent or delay the progressive loss of nigral DA neurons in genetically susceptible populations.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 021405573

Download citation: RISBibTeXText

PMID: 17720159

DOI: 10.1016/j.expneurol.2007.07.004


Related references

Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson's disease. Progress in Neurobiology 98(2): 207-221, 2012

The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. International Journal of Molecular Sciences 19(3), 2018

Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: potential therapeutic targets?. Neuroscience Bulletin 28(5): 649-657, 2013

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Science Translational Medicine 2(52): 52ra73, 2011

Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease. Current Drug Targets 5(2): 197-206, 2004

Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. Progress in Neurobiology 85(2): 135-147, 2008

Insulin-associated neuroinflammatory pathways as therapeutic targets for traumatic brain injury. Medical Hypotheses 82(2): 171-174, 2014

Potential therapeutic targets for Parkinson's disease. Expert Opinion on Therapeutic Targets 12(4): 425-436, 2008

Kinase signaling pathways as potential targets in the treatment of Parkinson's disease. Expert Review of Proteomics 4(6): 783-792, 2007

Network modeling to identify new mechanisms and therapeutic targets for Parkinson's disease. Expert Review of Neurotherapeutics 13(6): 685-693, 2014

Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention. Life Sciences 208: 1-9, 2018

Disease Pathways and Mechanisms of Potential Drug Targets. Clinical Liver Disease 12(1): 12-18, 2019

Current surgical treatments for Parkinson's disease and potential therapeutic targets. Neural Regeneration Research 13(8): 1342-1345, 2018

The Landscape of Parkin Variants Reveals Pathogenic Mechanisms and Therapeutic Targets in Parkinson's Disease. Human Molecular Genetics 2019, 2019

Developmental phenotypes and causal pathways in attention deficit/hyperactivity disorder: potential targets for early intervention?. Journal of Child Psychology and Psychiatry, and Allied Disciplines 51(4): 368-389, 2010